Screener
Gilead Sciences GILD Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value |
|---|---|---|---|---|
| U.S. treasury securities | $1,222 | $3 | — | $1,224 |
| U.S. government agencies securities | 15 | — | — | 15 |
| Corporate debt securities | 1,392 | 7 | — | 1,398 |
| Residential mortgage and asset-backed securities | 405 | 2 | — | 407 |
| Total | $3,033 | $11 | $(1) | $3,044 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's unrealized gains on investments?
- Gilead Sciences (GILD) reported unrealized gains on investments of $11M in Q4 2025.
- What is the long-term trend for Gilead Sciences's unrealized gains on investments?
- Over 4 years (2020 to 2025), Gilead Sciences's unrealized gains on investments has grown at a 38.4% compound annual growth rate (CAGR), from $3M to $11M.
- What does unrealized gains on investments mean?
- The total unrealized gains on investments, typically related to available-for-sale securities.
Ask your AI about Gilead Sciences's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude